Advances in the adjuvant treatment of colorectal cancer

ANZ Journal of Surgery

Volumn 76, Issue 5, 2006, Pages 373-380

  Nordman, Ina C ^a   Iyer, Shoba ^a   Joshua, Anthony M ^c   Clarke, Stephen J ^b  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b ANZAC Research Institute   (Australia)

^c PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

5 FU; Adjuvant; Colorectal cancer; Irinotecan; Oxaliplatin

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTICONVULSIVE AGENT; ATROPINE; BEVACIZUMAB; CALCIUM; CAPECITABINE; CETUXIMAB; ERLOTINIB; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; LEVAMISOLE; LOMUSTINE; LOPERAMIDE; OXALIPLATIN; PROTEIN TYROSINE KINASE INHIBITOR; TEGAFUR; VINCRISTINE;

ABDOMINAL CRAMP; BLEEDING; BLOOD TOXICITY; BRADYCARDIA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CHOLINERGIC SYNDROME; CLINICAL TRIAL; COLORECTAL CANCER; DIAPHORESIS; DIARRHEA; DISEASE FREE SURVIVAL; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; FEBRILE NEUTROPENIA; FEVER; GASTROINTESTINAL DISEASE; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; KIDNEY DISEASE; LACRIMATION; META ANALYSIS; MUCOSA INFLAMMATION; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PROTEINURIA; REVIEW; SALIVATION; SENSORY NEUROPATHY; SEPSIS; SIDE EFFECT; STATISTICAL SIGNIFICANCE; STOMATITIS; SYSTEMATIC REVIEW; THROMBOSIS; VOMITING;

ANTINEOPLASTIC AGENTS; AUSTRALIA; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; HUMANS; PHYSICIAN'S PRACTICE PATTERNS;

EID: 33744741058     PISSN: 14451433     EISSN: 14452197     Source Type: Journal    
DOI: 10.1111/j.1445-2197.2006.03726.x     Document Type: Review

References (77)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001 2 : 533 43.
2. Australian Institute of Health and Welfare Cited 15 Apr 2004 Available from URL : http://www.aihw.gov.au/
3. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J. Natl Cancer Inst. 2004 96 : 1420 25.
4. Obrand DI, Gordon PH. Incidence and patterns of recurrence following curative resection for colorectal carcinoma. Dis. Colon Rectum. 1997 40 : 15 24.
5. Myers CE, Diasio RB, Eliot HM et al. Pharmacokinectics of the fluoropyrimidines: implications for their clinical use. Cancer Treat. Rev. 1975 3 : 175 83.
6. Meta-analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J. Clin. Oncol. 1998 16 : 301 8.
7. Lokich JJ. Optimal schedule for 5-fluorouracil chemotherapy. Intermittent bolus or continuous infusion? Am. J. Clin. Oncol. 1985 8 : 445 8.
8. de Gramont A, Krulik M, Cady J et al. High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer. Eur. J. Cancer Clin. Oncol. 1988 24 : 1499 503.
9. Vardy J, Engelhardt K, Cox K et al. Long-term outcome of radiological-guided insertion of implanted central venous access port devices (CVAPD) for the delivery of chemotherapy in cancer patients: institutional experience and review of the literature. Br. J. Cancer 2004 91 : 1045 9.
10. Poon MA, O'Connell MJ, Moertel CG et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J. Clin. Oncol. 1989 7 : 1407 18.
11. Miwa M, Ura M, Nishida M et al. Design of novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-Fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur. J. Cancer 1998 43 : 1274 81.
12. Saltz LB. Understanding and managing chemotherapy-induced diarrhea. J. Support. Oncol. 2003 1 : 35 46.
13. Abigerges D, Armand JP, Chabot GG et al. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J. Natl Cancer Inst. 1994 86 : 446 9.
14. Tashiro T, Kawada Y, Sakurai Y, Kidani Y. Antiumour activity of a new platinum complex, oxalate (trans-1,1,2-diaminocy-clohexane) platinum (ii): new experimental data. Biomed. Pharmacother. 1989 43 : 251 60.
15. Faivre S, Chan D, Salinas R, Woynarowska B, Woynarowski JM. DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells. Biochem. Pharmacol. 2000 66 : 225 37.
16. Gamelin E, Gamelin L, Bossi L, Quasthoff S. Clinical aspects and molecular basis of oxaliplatin neurotoxicity; current management and development of preventative measures. Semin. Oncol. 2002 29 Suppl 15 21 33.
17. Carpenter G, Cohen S. Epidermal growth factor. J. Biol. Chem. 1990 265 : 7709 12.
18. Di Marco E, Pierce JG, Fleming TP et al. Autocrine interaction between TGF alpha and the EGF receptor: quantitative requirements for induction of the malignant phenotype. Oncogene 1989 4 : 831 8.
19. Wu X, Fan Z, Masui H et al. Apoptosis induced by antiepidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J. Clin. Invest. 1999 95 : 1897 905.
20. Xu X, Rubin M, Fan Z et al. Involvement of p27KIP1 in G1 arrest mediated by an epidermal growth factor receptor monoclonal antibody. Oncogene 1999 12 : 1397 403.
21. Fax Z, Shang BY, Wu X et al. Blockade of epidermal growth factor receptor by anti-EGFR monoclonal antibody 225 causes G1 arrest of A431 cells with induction of p27KIP1. Proc. Am. Assoc. Cancer Res. 1996 17 : 10.
22. Peng D, Fan Z, Lu Y et al. Anti-epidermal growth factor monoclonal antibody 225 upregulates p27KIP1 and induced G1 arrest in prostatic cancer cell lineDU145. Cancer Res. 1996 56 : 3666 9.
23. Chung KY, Shia J, Kemeny NE et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J. Clin. Oncol. 2005 23 : 1803 10.
24. Saltz LB, Meropol NJ, Loehrer PJ Sr., Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 2004 22 : 1201 8.
25. Frank RE, Saclarides TJ, Leurgans S et al. Tumor angiogenesis as a predictor of recurrence and survival in patients with node-negative colon cancer. Ann. Surg. 1995 222 : 695 9.
26. Takebayashi Y, Akiyama S, Yamada K et al. Angiogenesis as an unfavorable prognostic factor in human colorectal carcinoma. Cancer 1996 78 : 226 31.
27. Tanigawa N, Amaya H, Matsumura M et al. Tumor angiogenesis and mode of metastasis in patients with colorectal cancer. Cancer Res. 1997 57 : 1043 6.
28. Tomisaki S, Ohno S, Ichiyoshi Y et al. Microvessel quantification and its possible relation with liver metastasis in colorectal cancer. Cancer 1996 77 : 1722 8.
29. Choi HJ, Hyun MS, Jung GJ et al. Tumor angiogenesis as a prognostic predictor in colorectal carcinoma with special reference to mode of metastasis and recurrence. Oncology 1998 55 : 575 81.
30. Fox SH, Whalen GF, Sanders MM et al. Angiogenesis in normal tissue adjacent to colon cancer. J. Surg. Oncol. 1998 69 : 230 34.
31. Abdalla SA, Behzad F, Bsharah S et al. Prognostic relevance of microvessel density in colorectal tumours. Oncol. Rep. 1999 6 : 839 42.
32. Takahashi Y, Kitadai Y, Bucana CD et al. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 1995 55 : 3964 8.
33. Takahashi Y, Tucker SL, Kitadai Y et al. Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Arch. Surg. 1997 132 : 541 6.
34. Warren RS, Yuan H, Matli MR et al. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J. Clin. Invest. 1995 95 : 1789 97.
35. Radinsky R, Ellis LM. Molecular determinants in the biology of liver metastasis. Surg. Oncol. Clin. N. Am. 1996 5 : 215 29.
36. Tokunaga T, Oshika Y, Abe Y et al. Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer. Br. J. Cancer 1998 77 : 998 1002.
37. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004 350 : 2335 42.
38. Buyse M, Zeleniuch-Jacquotte A, Chalmers TC. Adjuvant therapy of colorectal cancer. Why we still don't know. JAMA 1988 259 : 3571 8.
39. Laurie JA, Moertel CG, Fleming TR et al. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J. Clin. Oncol. 1989 7 : 1447 56.
40. Moertel CG, Fleming TR, Macdonald JS et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage 3 colon carcinoma: a final report. Ann. Intern. Med. 1995 122 : 321 6.
41. Moertel CG, Fleming TR, Macdonald JS et al. Levamisole and fluorouracil as adjuvant therapy of resected colon carcinoma. N. Engl. J. Med. 1990 322 : 352 8.
42. Wolmark N, Fisher B, Rockette H et al. Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. J. Natl Cancer Inst. 1988 80 : 30 36.
43. Smith RE, Colangelo L, Wieand HS, Begovic M, Wolmark N. Randomised trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP C-01 protocol. J. Natl Cancer Inst. 2004 96 : 1128 32.
44. Wolmark N, Rockette H, Fisher B et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-03. J. Clin. Oncol. 1993 11 : 1879 87.
45. NIH Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990 264 : 1444 50.
46. Wolmark N, Rockette H, Mamounas E et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin and levamisole in patients with Duke's B and C carcinoma of the colon: results from the National Surgical Adjuvant Breast and Bowel Project C-04. J. Clin. Oncol. 1999 17 : 3553 9.
47. Porschen R, Bermann A, Löffler T et al. Fluorouracil plus leucovorin as effective adjuvant chemotherapy in curatively resected stage 3 colon cancer: results of the trial adjCCA-01. J. Clin. Oncol. 2001 15 : 1787 94.
48. O'Connell MJ, Laurie JA, Kahn M et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J. Clin. Oncol. 1998 16 : 295 300.
49. Haller DG, Catalano DJ, Macdonald JS et al. Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: five year report of INT-0089 (Abstract 982). Proc. Am. Soc. Clin. Oncol. 1998 17 : 256a.
50. QUASAR Collaborative Group. Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. Lancet 2000 355 : 1588 96.
51. Gill S, Loprinzi CL, Sargent DJ et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J. Clin. Oncol. 2004 22 : 1797 806.
52. Le Voyer TE, Sigurdson ER, Hanlon AL et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J. Clin. Oncol. 2003 21 : 2912 19.
53. Patel K, Anthoney DA, Crellin AM, Sebag-Montefiore D, Messruther J, Seymour MT. Weekly 5-fluorouracil and leucovorin: achieving lower toxicity with higher dose-intensity in adjuvant chemotherapy after colorectal cancer resection. Ann. Oncol. 2004 4 : 568 73.
54. Zaniboni A, Labianca R, Marsoni S et al. GIVIO-SITAC 01: a randomized trial of adjuvant 5-fluorouracil and folinic acid administered to patients with colon carcinoma - long term results and evaluation of the indicators of health-related quality of life. Gruppo Italiano Valutazione Interventi in Oncologia. Studio Italiano Terapia Adiuvante Colon. Cancer 1998 82 : 2135 44.
55. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 1995 345 : 939 44.
56. Francini G, Petrioli R, Lorenzini L et al. Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. Gastroenterology 1994 106 : 899 906.
57. O'Connell MJ, Mailliard JA, Kahn MJ et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J. Clin. Oncol. 1997 15 : 246 50.
58. Poplin E, Benedetti J, Estes N et al. Phase 3 randomised trial of bolus 5FU/leucovorin/levamisole versus 5-FU continuous infusion/levamisole as adjuvant treatment for high-risk colon cancer (SWOG 9415/INT-0153) (Abstract 931). Proc. Am. Soc. Clin. Oncol. 2000 19 : 240a.
59. Andre T, Colin P, Louvet C et al. Bimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J. Clin. Oncol. 2003 21 : 2896 903.
60. Saini A, Cunningham A, Norman AR et al. Multicentre randomised trial of protracted venous infusion 5-FU compared to 5-FU/folinic acid as adjuvant therapy for colon cancer (Abstract 928). Proc. Am. Soc. Clin. Oncol. 2000 19 : 240a.
61. Wils J. The establishment of a large collaborative trial programme in the adjuvant treatment of colon cancer. Br. J. Cancer 1998 77 Suppl 2 23 8.
62. Andre T, Boni C, Mounedji-Boudiaf L et al. Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N. Engl. J. Med. 2004 350 : 2343 51.
63. de Gramont A, Boni C, Navarro M et al. Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: efficacy results with a median follow-up of 4 years. Proc. Am. Soc. Clin. Oncol. 2005 23 : 3501.
64. Wolmark N, Wieand HS, Kuebler JP, Colangelo L, Smith RE. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: results of NSABP Protocol C-07 (Abstract 3500). Proc ASCO Annual Meeting 2005.
65. Scheithauer W, McKendrick J, Begbie S et al. Oral capecitabine as an alternative to IV 5-fluourouracil-based adjuvant therapy for colon cancer: safety results of a randomised phase 3 trial. Ann. Oncol. 2003 14 : 1735 43.
66. Twelves C, Wong A, Nowacki MP et al. Capecitabine as adjuvant treatment for stage III colon cancer. N. Engl. J. Med. 2005 352 : 2696 704.
67. Twelves C, Wong A, Nowacki MP et al. Capecitabine as adjuvant treatment for stage III colon cancer. N. Engl. J. Med. 2005 352 : 2696 704.
68. Saltz LB, Niedzwiecki D, Hollis D et al. Irinotecan plus fluourouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage 3 colon cancer (Intergroup trial CALGB C89803) (Abstract 3500). Proc. Am. Soc. Clin. Oncol. 2004 22 : 3500.
69. van Cutsem E, Labianca R, Hossfeld D et al. Randomized phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients (pts). (PETACC 3) (Abstract LBA8). Am. Soc. Clin. Oncol. 2005 23 : LBA8.
70. Barton M, Gabriel GS, Miles S. Colorectal cancer patterns of care in the Western Sydney and Wentworth Area Health Services. ANZ J. Surg. 2004 74 : 406 12.
71. National Health and Medical Research Council. Guidelines for the Prevention, Early Detection and Management of Colorectal Cancer (CRC). Canberra : Commonwealth of Australia, 1999.
72. Canna K, McMillan DC, McKee RF, McNicol AM, Horgan PG, McArdle CS. Evaluation of a cumulative prognostic score based on the systemic inflammatory response in patients undergoing potentially curative surgery for colorectal cancer. Br. J. Cancer 2004 90 : 1707 9.
73. Canna K, McArdle PA, McMillan DC et al. The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Br. J. Cancer 2005 92 : 651 4.
74. Nikiteas NI, Tzanakis N, Gazouli M et al. Serum IL-6, TNFalpha and CRP levels in Greek colorectal cancer patients: prognostic implications. World J. Gastroenterol. 2005 11 : 1639 43.
75. Buckowitz A, Knaebel HP, Benner A et al. Microsatellite instability in colorectal cancer is associated with local lymphocyte infiltration and low frequency of distant metastases. Br. J. Cancer 2005 92 : 1746 53.
76. Eschrich S, Yang I, Bloom G et al. Molecular staging for survival prediction of colorectal cancer patients. J. Clin. Oncol. 2005 23 : 3526 35.
77. Hassan AB, Paraskeva C. Colorectal cancer prognosis: is it all mutation, mutation, mutation? Gut 2005 54 : 1209 11.